Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Avantis US Small Cap Value ETF (AVUV) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance

Avantis US Small Cap Value ETFTrade
State Street SPDR S&P Biotech ETFTrade

Price performance (Past 24H)

Key statistics

Avantis US Small Cap Value ETF vs State Street SPDR S&P Biotech ETF — how do they compare? Avantis US Small Cap Value ETF trades at $127.78, while State Street SPDR S&P Biotech ETF trades at $159.35. Which is the better fit depends on your goals.

AVUVXBI
Sector
Sector/ThematicBroad Market / Factor
52-Week High
$128.74$164.28
52-Week Low
$93.93$86.92

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Avantis US Small Cap Value ETF

AVUV, a U.S. small-cap value ETF, trades at $127.51, up 0.4% today, with a bullish technical signal from moving averages and neutral oscillators. Recent news highlights its strong 2026 performance, outpacing the Russell 2000, and positioning it as a diversification tool for tech-heavy portfolios. The fund benefits from a shift toward value stocks and potential rate cut tailwinds.

The outlook for AVUV is positive, driven by small-cap value momentum and investor rotation away from large-cap concentration. Key risks include sensitivity to interest rates, regional bank exposure, and higher small-cap volatility. Analyst sentiment is optimistic, with media coverage emphasizing its role in balanced long-term strategies.

State Street SPDR S&P Biotech ETF

XBI, the SPDR S&P Biotech ETF, trades at $159.39, up 0.86% on the day, with a bullish technical signal driven by moving averages. The fund holds 155 biotech stocks, benefiting from strong sector momentum, including a 17% gain in June 2026 (ETF Trends, 2026-07-01). Recent news highlights institutional buying and positive drug trial outcomes fueling the rally.

Outlook: Biotech sector tailwinds from M&A, AI drug discovery, and clinical successes support further upside, but high volatility and policy risks persist. Investors gain diversified exposure to small- and mid-cap biotech innovation, though the 0.35% expense ratio and lack of dividend yield may deter income-focused buyers.

Returns comparison

Trailing returns across standard periods

About Avantis US Small Cap Value ETF

AVUV is an actively managed ETF that targets small-cap value companies in the United States. It uses a systematic, rules-based process to identify firms with low valuations and high profitability, aiming to capture the historical premiums of 'size' and 'value' while filtering for financial quality.

Read more on AVUV

About State Street SPDR S&P Biotech ETF

XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.

Read more on XBI